IGF1 and cancer: Experiments using exogenous, recombinant forms of TGF-β1, HGF, GRO-1, and IGF-1 applied to respective cells at doses corresponding to their concentration in MAs provided clarification that both normal and cancer cells are sensitive to the identified mediators, which makes them responsible for the MAs-dependent increase in cancer cell adhesion (Figure 5).